Resources/Journal
Journal
Research write-ups, new compound deep dives, and updates from the Canada Peptides team.
blog
6 min
Glutathione side effects — what the research reports
Glutathione side effects by evidence tier: what oral, intravenous, intranasal and inhaled trials recorded, the regulatory alerts on unapproved IV use, and why the vial matters as much as the molecule.
blog
6 min
NAD+ side effects — what the research reports
NAD+ side effects by evidence tier: the 2019 infusion study, rate-dependent flushing, chest tightness and nausea in clinic infusions, oral NR and NMN trials, and why precursor data is not NAD+ data.
blog
6 min
DSIP side effects — what the research reports
DSIP side effects by evidence tier: what the 1980s intravenous human studies recorded, what animal toxicology found, the uncontrolled reports on subcutaneous use, and the forty-year data gap.
blog
6 min
Selank side effects — what the research reports
Selank side effects by evidence tier: what the Russian anxiety trials recorded against benzodiazepine comparators, the sedation and dependence claims, the immune thread, and what is untested.
blog
6 min
Semax side effects — what the research reports
Semax side effects by evidence tier: what the Russian registration label and clinical series describe, what rodent work adds, the uncontrolled reports, and the gaps a Western trial would fill.
blog
6 min
Epithalon side effects — what the research reports
Epithalon side effects by evidence tier: what the Russian human series and the lifelong mouse study recorded, what that tier cannot show, the telomerase question and purity as a confound.
blog
6 min
Melanotan II dosage — research dosing notes
What the University of Arizona studies report about Melanotan II dosage: 0.01–0.03 mg/kg subcutaneous in the 1990s trials, the ~1-hour half-life, and the reconstitution arithmetic for a 10 mg vial.
blog
6 min
KPV side effects — what the research reports
KPV side effects by evidence tier: no human safety data exists, what the mouse colitis and skin studies did and did not look for, mechanistic considerations, purity as a confound and Canadian status.
blog
6 min
KPV dosage — research dosing notes
What the literature reports about KPV dosage: the oral, intraperitoneal and topical amounts used in mouse colitis and skin models, why there is no human dosing data, and 10 mg vial arithmetic.
blog
6 min
Thymosin alpha-1 side effects — what the research reports
Thymosin alpha-1 side effects by evidence tier: tolerability recorded in the thymalfasin trials and Zadaxin post-marketing record, the mechanistic cautions and the gaps for research-grade material.
blog
6 min
Thymosin alpha-1 dosage — research dosing notes
What the thymalfasin trials and the Zadaxin label report about thymosin alpha-1 dosage: the 1.6 mg subcutaneous unit dose, its cadences, the 2-hour half-life and 5 mg vial arithmetic.
blog
6 min
HCG side effects — what the research reports
hCG side effects by evidence tier: the approved-product monograph (OHSS, gynaecomastia, oedema, injection-site reactions), the small adjunct trials, and the gaps for research-grade material.
blog
6 min
HCG dosage — research dosing notes
What the labelling and literature report on hCG dosing: why it is measured in IU, the 24–36 hour half-life, approved-product regimens, the 125–500 IU studies, and IU/mL arithmetic for a 5,000 IU vial.
blog
6 min
Kisspeptin side effects — what the research reports
Kisspeptin side effects by evidence tier: what several hundred volunteers in the human physiology and IVF studies showed, the predictable endocrine effects, tachyphylaxis, and the gaps.
blog
6 min
Kisspeptin dosage — research dosing notes
What the human kisspeptin studies reported: kisspeptin-10 versus kisspeptin-54, intravenous and subcutaneous doses, the IVF-trigger trials, tachyphylaxis, and reconstitution math for a 10 mg vial.
blog
6 min
Cerebrolysin side effects — what the research reports
Cerebrolysin side effects by evidence tier: the Cochrane finding of increased serious adverse events after stroke, the labelled reaction profile, rapid-injection effects and the gaps.
blog
6 min
Cerebrolysin dosage — research dosing notes
How the Cerebrolysin trials administered it: 30 mL IV daily for 10 days in CASTA, 21 days in CARS, the dementia and TBI regimens, the labelled routes, and why there is no reconstitution or half-life.
blog
6 min
Tesofensine side effects — what the research reports
Tesofensine side effects by evidence tier: the dose-dependent heart-rate and blood-pressure rise, dry mouth, insomnia and mood signals from the Phase 2 and 3 trials, and the gaps.
blog
6 min
Tesofensine dosage — research dosing notes
What the tesofensine trials administered: the 0.25–1.0 mg once-daily oral doses of TIPO-1 and the Mexican Phase 3, the nine-day half-life and weeks-long accumulation, and titration.
blog
6 min
AOD-9604 side effects — what the research reports
AOD-9604 side effects by evidence tier: the pooled six-trial tolerability data from the oral Phase 1 and 2 programme, the GRAS and FDA positions, animal work, and the injectable-route gap.
blog
6 min
AOD-9604 dosage — research dosing notes
What the literature reports on AOD-9604 dosage: the 1–30 mg oral trial doses, rodent mg/kg protocols, the absent injectable half-life, and reconstitution math for a 2.5 mg vial.
blog
6 min
HGH Fragment 176-191 side effects — what the research reports
HGH Fragment 176-191 side effects by evidence tier: the oral AOD-9604 trial tolerability data, what rodent work adds, what self-report cannot show, and the injectable-route gap.
blog
6 min
HGH Fragment 176-191 dosage — research dosing notes
What the literature reports on HGH Fragment 176-191 dosage: rodent mg/kg protocols, the oral AOD-9604 trial doses, the missing half-life, and reconstitution math for a 5 mg vial.
blog
6 min
SLU-PP-332 side effects — what the research reports
SLU-PP-332 side effects by evidence tier: no human data of any kind, what the short mouse studies did and did not measure, the cardiac and carcinogenicity questions, and Canadian and WADA status.
blog
6 min
SLU-PP-332 dosage — research dosing notes
SLU-PP-332 dosage as the literature reports it: the 50 mg/kg twice-daily intraperitoneal mouse regimen, the DMSO vehicle, the absence of any human data, and stock-solution arithmetic for a 30 mg vial.
blog
6 min
Tesamorelin side effects — what the research reports
Tesamorelin side effects from the Egrifta Phase 3 trials and monograph: injection-site reactions, arthralgia, oedema, glucose and IGF-1 signals, and why none of it transfers to research-grade vials.
blog
6 min
CJC-1295 side effects — what the research reports
CJC-1295 side effects by evidence tier: the 2006 human trials of the DAC form, why sustained GH and IGF-1 elevation is the key DAC vs no-DAC difference, the gaps, and Canadian and WADA status.
blog
6 min
Ipamorelin side effects — what the research reports
Ipamorelin side effects by evidence tier: the intravenous Phase 1 and Phase 2 tolerability data, rodent findings, GH-secretagogue class effects, the gaps, and Canadian and WADA status.
blog
6 min
GHRP-6 side effects — what the research reports
GHRP-6 side effects by evidence tier: the hunger that follows from its ghrelin receptor, what single-dose human studies recorded, the animal cytoprotection data, and what no trial has measured.
blog
6 min
GHRP-6 dosage — research dosing notes
What the literature reports on GHRP-6 dosage: the 1 µg/kg intravenous bolus, subcutaneous, intranasal and oral routes, animal cadences, the 15–60 minute half-life and 5 mg vial reconstitution math.
blog
6 min
GHRP-2 side effects — what the research reports
GHRP-2 side effects by evidence tier: the approved diagnostic's labelling, the cortisol, ACTH and prolactin signals from controlled studies, paediatric courses, and what no adult trial has measured.
blog
6 min
GHRP-2 dosage — research dosing notes
What the literature reports on GHRP-2 dosage: the 100 µg diagnostic bolus, µg/kg doses by route, the eight-month paediatric courses, the ~1 h half-life and 5 mg vial reconstitution math.
blog
5 min
DSIP dosage — research dosing notes
A literature review of DSIP dosage: why the human studies all used 25 nmol/kg intravenously, how that converts to micrograms, reconstitution math, and DSIP's minutes-long plasma half-life.
blog
6 min
Selank dosage — research dosing notes
What the published literature reports on selank dosage: the 300 µg/kg rodent reference dose, the intranasal clinical record, half-life context, and reconstitution math for a 5 mg vial. Research reference only.
blog
6 min
Epithalon dosage — research dosing notes
What the published literature reports about epithalon dosage: the doses and course cadences used in the AEDG research record, reconstitution math for a 10 mg vial, and the missing pharmacokinetic data. Research context, not dosing advice.
blog
5 min
GHK-Cu side effects — what the research reports
What the literature actually reports about GHK-Cu side effects: the mild, transient local reactions from topical dermatology trials, copper hypersensitivity data, the copper-load arithmetic, and the missing injectable safety record.
blog
6 min
PT-141 side effects — what the research reports
PT-141 side effects from the phase 3 bremelanotide trials and FDA label: nausea, flushing, transient blood pressure changes, focal hyperpigmentation, and where the data runs out.
blog
5 min
MOTS-c side effects — what the research reports
MOTS-c side effects have never been characterized in a completed human trial. What the CB4211 analog study, rodent work, and uncontrolled self-report actually show — and where the data stops.
blog
5 min
TB-500 side effects — what the research reports
TB-500 side effects, separated by evidence tier: what the human thymosin β4 trials actually recorded, what uncontrolled self-report adds, and the gaps neither covers.
blog
6 min
CJC-1295 + Ipamorelin — a research overview of the blend
A research overview of the CJC-1295 ipamorelin blend: the GHRH-plus-GHRP synergy evidence, why the no-DAC form is the conventional partner, and where the human data actually stops.
blog
6 min
PT-141 dosage — research dosing notes
What the literature reports on PT-141 dosage: the 1.75 mg subcutaneous regimen from the RECONNECT Phase 3 trials, the ~2.7-hour half-life, the eight-dose monthly ceiling, and reconstitution math for a 10 mg vial.
blog
6 min
CJC-1295 — a research overview
A research overview of the CJC-1295 peptide: GHRH-analogue mechanism, the DAC albumin-binding chemistry, what the 2006 human trials measured, and why development stopped.
blog
6 min
Melanotan 2 side effects — what the research reports
What the published literature actually reports about Melanotan 2 side effects: the dose-limiting effects from the only human trial, the melanocytic and naevus signal, the systemic case reports, and the limits of the data.
blog
5 min
AOD-9604 — a research overview
A research overview of the AOD-9604 peptide: the hGH 177-191 fragment, its proposed β3-adrenergic lipolysis mechanism, what the Phase 2a and Phase 2b human trials actually returned, and its regulatory status.
blog
6 min
Cerebrolysin — a research overview
A research overview of the cerebrolysin peptide preparation: what the porcine brain hydrolysate actually is, what its mechanism claims do and don't support, and how its contested stroke, vascular dementia and TBI trial data reads.
blog
6 min
PT-141 (Bremelanotide) — a research overview
A research overview of the PT-141 peptide (bremelanotide): MC4R mechanism, RECONNECT Phase 3 trial data, pharmacokinetics, and the tolerability limits reported in the published literature.
blog
6 min
NAD+ dosage — research dosing notes
What the literature actually reports on NAD+ dosage: the 750 mg six-hour intravenous protocol from Grant 2019, the oral NR and NMN dose-ranging trials, why infusion rate matters more than total milligrams, and reconstitution math for a 500 mg vial.
blog
7 min
Glutathione dosage — research dosing notes
What the literature reports on glutathione dosage: the ~14-minute intravenous half-life, the 600 mg and 1,400 mg IV Parkinson's protocols, the six-month oral dose-response trial, and reconstitution math for a 600 mg vial.
blog
6 min
Tesamorelin vs Ipamorelin — compared
Tesamorelin vs ipamorelin compared: GHRH analog versus ghrelin-receptor agonist, half-life, approval status, and how far apart the human evidence actually sits.
blog
6 min
Epithalon vs MOTS-c — longevity peptides compared
Epithalon vs MOTS-c: telomerase and circadian signalling against mitochondrial AMPK activation — mechanisms, half-life, and what the published research actually supports for each.
blog
6 min
GLOW blend — a research overview
The GLOW peptide blend combines GHK-Cu, BPC-157 and TB-500 in one vial. A research overview of what each component's literature actually supports — and what the blend itself has never been studied for.
blog
6 min
KLOW blend — a research overview
The KLOW peptide blend combines GHK-Cu, BPC-157, TB-500 and KPV in one vial. A research overview of what each component's literature supports — and what the blend itself has never been studied for.
blog
6 min
Semaglutide vs Tirzepatide — compared
Semaglutide vs tirzepatide compared on mechanism, half-life, and the head-to-head trial data from SURPASS-2 and SURMOUNT-5 — including where the cardiovascular evidence still diverges.
blog
5 min
Semax vs Selank — compared
Semax vs Selank compared across sequence, mechanism, half-life, registered indications and depth of evidence — and where the shared Pro-Gly-Pro design stops being a shared mechanism.
blog
6 min
Ipamorelin vs CJC-1295 — compared
Ipamorelin vs CJC-1295: two different receptors, two different half-lives, two different depths of human data. A research comparison of the ghrelin-receptor agonist and the long-acting GHRH analog.
blog
6 min
GHRP-2 vs GHRP-6 — compared
GHRP-2 vs GHRP-6 compared across sequence, receptor pharmacology, half-life, GH response and appetite — including where the common claim that GHRP-2 avoids hunger breaks down against the published data.
blog
5 min
Semax dosage — research dosing notes
What the literature actually reports on Semax dosage: the 0.1% and 1% intranasal concentrations, the 6,000 µg/day post-stroke regimen, half-life context, and reconstitution math for a 5 mg vial.
blog
5 min
MOTS-c dosage — research dosing notes
What the literature actually reports on MOTS-c dosage: the rodent mg/kg ranges from Lee 2015 and Reynolds 2021, the human trial regimens, half-life context, and reconstitution math for a 10 mg vial.
blog
6 min
GHK-Cu dosage — research dosing notes
A research overview of GHK-Cu dosage: the 0.1–2% topical concentrations used in published trials, the preclinical injected figures, the short circulating half-life, and reconstitution math for lyophilized vials. Literature summary only, not medical advice.
blog
5 min
CJC-1295 dosage — research dosing notes
A literature review of CJC-1295 dosage: the weight-scaled weekly doses used in the published human trials of the DAC form, the half-life data behind that cadence, and reconstitution math for a 10 mg research vial.
blog
6 min
Tesamorelin dosage — research dosing notes
A research reference on tesamorelin dosage: the fixed 2 mg daily dose used across the phase 3 trials, why the three approved formulations list different milligram figures, the sub-hour half-life, and the reconstitution math. A literature overview, not medical advice.
blog
6 min
BPC-157 dosage — research dosing notes
A literature review of BPC-157 dosage: the animal dose ranges actually studied, the measured pharmacokinetics in rats and dogs, and why no human dose has been established. Research use only.
blog
6 min
Tirzepatide dosage — research dosing notes
A literature overview of tirzepatide dosage: the 2.5 mg initiation step, four-week titration cadence, and 5/10/15 mg maintenance levels used in the trials, the ~5-day half-life behind once-weekly dosing, and reconstitution math for lyophilized vials. Research context only, not medical advice.
blog
5 min
Semaglutide dosage — research dosing notes
A research-literature overview of semaglutide dosage: the STEP and SUSTAIN escalation schedules, the 7-day half-life behind the four-week cadence, and the reconstitution math from lyophilized vial to syringe units.
blog
5 min
Retatrutide dosage — research dosing notes
A research-framed overview of retatrutide dosage: the titration schedules and doses used in clinical trials, its ~6-day half-life, and reconstitution math. Research-use-only, not medical advice.
blog
5 min
Ipamorelin dosage — research dosing notes
A research overview of ipamorelin dosage: the reconstitution math, the intravenous doses and twice-daily cadence reported in the literature, and the ~2-hour half-life context — framed strictly as a laboratory-research reference, not medical advice.
blog
5 min
SLU-PP-332 — a research overview
A measured research overview of SLU-PP-332: how this pan-ERR agonist works as an exercise mimetic, what the rodent data actually shows, its pharmacokinetic limits, and why there is still no human evidence.
blog
6 min
TB-500 dosage — research dosing notes
A literature review of TB-500 dosage: what the published thymosin beta-4 trials actually dosed, the intravenous pharmacokinetics on record, and why no human dose has been established for the TB-500 fragment itself.
blog
6 min
HCG — a research overview
A measured research overview of the HCG peptide: its glycoprotein structure, LHCGR mechanism and cAMP signalling bias, the hypogonadotropic hypogonadism and ovulation-trigger data, and why the approved label rejects the obesity claim.
blog
5 min
Tesofensine — a research overview
A measured research overview of tesofensine: the triple monoamine reuptake inhibitor's mechanism, the TIPO-1 trial data, how it compares to GLP-1 peptides, and honest limits of the evidence.
blog
5 min
GHRP-6 — a research overview
A measured research overview of the GHRP-6 peptide: its ghrelin-receptor mechanism, growth-hormone and appetite effects, CD36 cytoprotective research, and how it compares to GHRP-2 and ipamorelin.
blog
5 min
GHRP-2 — a research overview
A measured research overview of the GHRP-2 peptide (pralmorelin): its ghrelin-receptor mechanism, the growth hormone, cortisol, and appetite data, and how it compares to GHRP-6 and ipamorelin.
blog
5 min
Melanotan 2 — a research overview
A measured research overview of melanotan 2: its melanocortin-receptor mechanism, how it compares to afamelanotide and PT-141, and the honest limits of the human data.
blog
5 min
DSIP — a research overview
A measured research overview of DSIP (delta sleep-inducing peptide): its structure, proposed mechanism, the mixed sleep and stress-axis data, and where the DSIP peptide sits versus related compounds.
blog
4 min
Generic Semaglutide in Canada: What Health Canada's 2026 Approvals Mean
Canada is the first G7 country to approve generic semaglutide. What Health Canada approved in 2026, why the patent lapsed, pricing and availability — and how prescription generics differ from research-grade semaglutide.
blog
4 min
KPV — a research overview
A measured research overview of the KPV peptide: what the lysine-proline-valine tripeptide is, its PepT1/NF-kB anti-inflammatory mechanism, the preclinical colitis and skin data, and honest limits.
blog
5 min
Kisspeptin — a research overview
A measured research overview of the kisspeptin peptide: its role upstream of GnRH in the HPG axis, the kisspeptin-10 vs kisspeptin-54 human trial data, and honest caveats on data maturity.
blog
5 min
Glutathione — a research overview
A measured research overview of the glutathione injection: its antioxidant biochemistry, the intravenous bioavailability rationale, and what Parkinson's and skin-lightening trials actually show.
blog
1 min
BPC-157 Dosing: A Research Reference
How BPC-157 is handled in research — administration route, reconstitution, and the dosing math. Research use only, not medical advice.
blog
1 min
BPC-157 Side Effects: What the Research Reports
What the literature reports about BPC-157 tolerability, framed for research. Research use only, not medical advice.
blog
1 min
BPC-157 Oral vs Injectable: What the Research Uses
Oral vs injectable BPC-157 — the routes seen in research and the stability considerations behind them. Research use only, not medical advice.
blog
1 min
Tirzepatide Side Effects: What the Research Reports
What the published literature reports about tirzepatide's tolerability and side-effect profile, framed for research. Research use only, not medical advice.
blog
1 min
Tirzepatide Dosing: A Research Reference
How tirzepatide is dosed in published research — once-weekly administration, titration, and reconstitution math. Research use only, not medical advice.
blog
1 min
Is Tirzepatide the Same as Mounjaro? Tirzepatide vs Mounjaro & Zepbound
Tirzepatide vs Mounjaro — the difference between a compound and its brand names. Mounjaro and Zepbound are tirzepatide; what research-grade tirzepatide is and isn't. Research use only.
blog
1 min
Semaglutide Side Effects: What the Research Reports
What the published literature reports about semaglutide's tolerability and side-effect profile, framed for research. Research use only, not medical advice.
blog
1 min
Semaglutide Dosing: A Research Reference
How semaglutide is dosed in published research — once-weekly administration, titration, and reconstitution math. Research use only, not medical advice.
blog
2 min
Is Semaglutide the Same as Ozempic? Semaglutide vs Ozempic
Semaglutide vs Ozempic — the difference between a compound and its brand names. Ozempic and Wegovy are semaglutide; what research-grade semaglutide is and isn't. Research use only.
blog
2 min
Retatrutide Side Effects: What the Research Reports
What published retatrutide trials report about tolerability and the side-effect profile of the triple agonist. Investigational compound — research use only, not medical advice.
blog
2 min
Retatrutide vs Ozempic (Semaglutide): How They Differ
Retatrutide vs Ozempic — a triple agonist versus a single GLP-1 agonist. Receptor coverage, mechanism, and what the trial data covers. Research use only.
blog
2 min
Retatrutide Dosing: A Research Reference
How retatrutide was dosed in published Phase 2/3 research — titration schedule, frequency, and the reconstitution math behind it. Research use only, not medical advice.
blog
4 min
Retatrutide Pen: How to Use It and Where to Buy in Canada
Retatrutide pen for sale in Canada — what the 15 mg reloadable 3 mL pen is, how to load, prime, and dose it, how it compares to vials, and where to buy it. Research use only.
blog
7 min
NAD+ — a research overview
NAD+ is the cell's central redox coenzyme and the substrate sirtuins and PARPs consume. A research overview of its mechanism, the bioavailability problem, precursor strategies, and what the human data actually shows.
blog
3 min
Semax — a research overview
Semax is a synthetic ACTH(4-10) analogue studied as a nootropic and neuroprotective peptide. Its mechanism, the BDNF/NGF neurotrophic story, and what the (Russia-dominated) research actually shows.
blog
4 min
Semaglutide — a research overview
Mechanism, half-life, dose-response curve, and the human literature behind the most-studied GLP-1 receptor agonist of the last decade.
blog
5 min
GLP-1 receptor agonists compared
Semaglutide vs Tirzepatide vs Retatrutide—mechanism, half-life, dosing, and the evidence gap.
blog
5 min
Tesamorelin — a research overview
Stabilized GHRH analogue with FDA approval for HIV lipodystrophy, selective visceral fat reduction, and pulse-amplification mechanism.
blog
6 min
BPC-157 vs TB-500—healing peptides compared
Two foundational soft-tissue research peptides, their distinct mechanisms, and why they're often stacked together.
blog
3 min
The four-phase research cycle
How to run a peptide protocol like an engineer — define the endpoint, measure the baseline, run the cycle, review the data.
blog
6 min
Storing peptides — the cold chain from shipping to vial
Lyophilized and reconstituted stability windows, temperature ranges, and practical storage logistics.
blog
7 min
Growth-hormone secretagogues—the category guide
GHRH analogues and GHRPs explained—mechanisms, selectivity, and why they're often combined.
blog
4 min
Tirzepatide — a research overview
Dual GIP/GLP-1 receptor agonist with extended half-life, dose-response curve, and the SURPASS and SURMOUNT trial literature.
blog
6 min
CJC-1295—with DAC or without?
Half-life, pulsatile vs continuous GH release, and why we carry both versions.
blog
6 min
Reading a peptide Certificate of Analysis — what to check
Anatomy of a COA, red flags, and how to verify identity and purity.
blog
6 min
Sleep & Longevity Peptides: DSIP, Epithalon, MOTS-c
DSIP, Epithalon, MOTS-c—three axes of biological aging and why they're discussed together.
blog
5 min
Retatrutide — a research overview
Triple GIP/GLP-1/glucagon receptor agonist in phase 3 development with emerging data on metabolic effects beyond appetite suppression.
blog
5 min
Thymosin Alpha-1 — a research overview
28-aa thymic peptide driving T-cell and NK-cell immunity, with established clinical use in hepatitis and emerging COVID-era research.
blog
6 min
What research-grade peptides mean — regulatory definitions and quality
RUO labeling, cGMP, purity specs, and the practical gap between grades.
blog
7 min
Skin Peptides Explained: Melanotan 2, GHK-Cu & KPV
Melanotan 2, GHK-Cu, KPV, and the blends—structural, pigmentation, and dermal research.
blog
5 min
Selank — a research overview
Synthetic anxiolytic heptapeptide with GABAergic and immunomodulatory roots, clinically approved in Russia for stress and anxiety.
blog
5 min
BPC-157 — a research overview
15-amino-acid peptide derived from gastric protein with pro-angiogenic and tissue-protective mechanisms across soft-tissue and neurological models.
blog
7 min
AOD-9604 vs HGH Fragment 176-191—the myth
They're the same peptide. The confusing names explained, the failed trials, and why we list both.
blog
5 min
Subcutaneous vs intramuscular injection — routes and pharmacokinetics
Absorption kinetics, needle sizing, injection sites, and when to choose each route.
blog
4 min
MOTS-c — a research overview
Mitochondrial-derived peptide regulating AMPK and metabolic aging, with emerging human data on insulin sensitivity and exercise physiology.
blog
5 min
TB-500 — a research overview
Synthetic Thymosin Beta-4 analog with G-actin binding activity, cell-migration effects, and a mixed pre-clinical/cross-species literature.
blog
4 min
Epithalon — a research overview
Synthetic pineal-mimicking tetrapeptide, telomerase activation claims, and why the Russian literature dominates the dataset.
blog
6 min
Peptide reconstitution basics — lyophilized to liquid
Diluent choice, volume math, syringe mechanics, and storage after reconstitution.
blog
5 min
Ipamorelin — a research overview
Selective GHRP/ghrelin agonist with GH-pulse amplification, minimal cortisol spillover, and common stacking protocols.
blog
5 min
GHK-Cu — a research overview
Copper-binding tripeptide mechanism, tissue distribution, and the dermal and systemic literature behind this naturally-occurring regulator.
blog
8 min
How peptides are made — synthesis 101
From amino acids to vial: solid-phase synthesis, coupling chemistry, cleavage, and purification.
blog
2 min
Why peptides, and why now
A brief landscape of where peptide research sits in 2026, why the GLP-1 wave unlocked adjacent categories, and what's next.
blog
3 min
How to read a peptide study
A compact framework for evaluating a peptide paper — what to check, what to discount, and how to tell mechanism from marketing.